566 related articles for article (PubMed ID: 36849435)
1. Molecular and functional imaging in cancer-targeted therapy: current applications and future directions.
Bai JW; Qiu SQ; Zhang GJ
Signal Transduct Target Ther; 2023 Feb; 8(1):89. PubMed ID: 36849435
[TBL] [Abstract][Full Text] [Related]
2. Are recist criteria adequate in assessing the response to therapy in metastatic NEN?
Vullierme MP; Ruszniewski P; de Mestier L
Rev Endocr Metab Disord; 2021 Sep; 22(3):637-645. PubMed ID: 33871762
[TBL] [Abstract][Full Text] [Related]
3. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
[TBL] [Abstract][Full Text] [Related]
4. Imaging biomarkers for evaluating tumor response: RECIST and beyond.
Ko CC; Yeh LR; Kuo YT; Chen JH
Biomark Res; 2021 Jul; 9(1):52. PubMed ID: 34215324
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy.
Desar IM; van Herpen CM; van Laarhoven HW; Barentsz JO; Oyen WJ; van der Graaf WT
Cancer Treat Rev; 2009 Jun; 35(4):309-21. PubMed ID: 19136215
[TBL] [Abstract][Full Text] [Related]
7. New strategy for monitoring targeted therapy: molecular imaging.
Teng FF; Meng X; Sun XD; Yu JM
Int J Nanomedicine; 2013; 8():3703-13. PubMed ID: 24124361
[TBL] [Abstract][Full Text] [Related]
8. Computed tomography and magnetic resonance imaging.
Bernsen MR; Ruggiero A; van Straten M; Kotek G; Haeck JC; Wielopolski PA; Krestin GP
Recent Results Cancer Res; 2013; 187():3-63. PubMed ID: 23179877
[TBL] [Abstract][Full Text] [Related]
9. Molecular imaging and targeted therapies in oncology: new concepts in treatment response assessment. a collection of cases.
Pantaleo MA; Nannini M; Lopci E; Castellucci P; Maleddu A; Lodi F; Nanni C; Allegri V; Astorino M; Brandi G; Di Battista M; Boschi S; Fanti S; Biasco G
Int J Oncol; 2008 Sep; 33(3):443-52. PubMed ID: 18695872
[TBL] [Abstract][Full Text] [Related]
10. Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response.
Wu M; Zhang Y; Zhang Y; Liu Y; Wu M; Ye Z
Radiol Imaging Cancer; 2019 Nov; 1(2):e190031. PubMed ID: 33778682
[TBL] [Abstract][Full Text] [Related]
11. Objective response rate assessment in oncology: Current situation and future expectations.
Aykan NF; Özatlı T
World J Clin Oncol; 2020 Feb; 11(2):53-73. PubMed ID: 32133275
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of lung tumor response to therapy: Current and emerging techniques.
Coche E
Diagn Interv Imaging; 2016 Oct; 97(10):1053-1065. PubMed ID: 27693090
[TBL] [Abstract][Full Text] [Related]
13. Translational imaging endpoints to predict treatment response to novel targeted anticancer agents.
Serkova NJ
Drug Resist Updat; 2011; 14(4-5):224-35. PubMed ID: 21640633
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the RECIST and EORTC PET criteria in the tumor response assessment: a pooled analysis and review.
Kim JH; Kim BJ; Jang HJ; Kim HS
Cancer Chemother Pharmacol; 2017 Oct; 80(4):729-735. PubMed ID: 28780726
[TBL] [Abstract][Full Text] [Related]
15. Computed Tomography and Magnetic Resonance Imaging.
Bernsen MR; van Straten M; Kotek G; Warnert EAH; Haeck JC; Ruggiero A; Wielopolski PA; Krestin GP
Recent Results Cancer Res; 2020; 216():31-110. PubMed ID: 32594384
[TBL] [Abstract][Full Text] [Related]
16. Synergistically integrated nanoparticles as multimodal probes for nanobiotechnology.
Cheon J; Lee JH
Acc Chem Res; 2008 Dec; 41(12):1630-40. PubMed ID: 18698851
[TBL] [Abstract][Full Text] [Related]
17. [Cancer treatment response evaluation based on imaging modalities, such as computed tomography, magnetic resonance imaging and FDG-PET].
Endo M; Aramaki T; Moriguchi M; Sawada A; Asakura K; Bekku E
Gan To Kagaku Ryoho; 2013 Mar; 40(3):294-8. PubMed ID: 23507590
[TBL] [Abstract][Full Text] [Related]
18. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
[TBL] [Abstract][Full Text] [Related]
19. Imaging beyond RECIST: CT and MRI in molecular therapies.
Diederich S
Cancer Imaging; 2012 Sep; 12(2):347-50. PubMed ID: 23023112
[TBL] [Abstract][Full Text] [Related]
20. Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria.
Krajewski KM; Nishino M; Franchetti Y; Ramaiya NH; Van den Abbeele AD; Choueiri TK
Cancer; 2014 Mar; 120(5):711-21. PubMed ID: 24264883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
